• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
ConclusionNo signal of DDIs between DOACs and antineoplastic agents was detected, except for DOAC-neratinib. Most DDIs between DOACs and antineoplastic agents may not be clinically relevant. The DDIs between DOACs and neratinib should be further examined in future research.
Source: Journal of Thrombosis and Thrombolysis - August 10, 2023 Category: Hematology Source Type: research

Controversial cardiovascular and hematologic comorbidities in atopic dermatitis
AbstractAtopic dermatitis ’ (AD) systemic involvement is wide-reaching. The cardiovascular and hematological comorbidities of AD have potential for considerable economic and physical burden; however, data surrounding the association between these comorbidities and AD is controversial. This review discusses the cardiovascul ar and hematological comorbidities of AD, detailing the conflicting evidence, pathophysiology, and connection to medications. A PubMed search was conducted for studies detailing the association of cardiovascular and hematological comorbidities with AD, providing approximately 30 results. Additional sea...
Source: Archives of Dermatological Research - April 13, 2022 Category: Dermatology Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Cyclosporine in acute ischemic stroke
Conclusions: Cyclosporine was generally not effective in reducing infarct size. However, a smaller infarct size was observed in patients with proximal cerebral artery occlusion and efficient recanalization. Classification of evidence: This study provides Class I evidence that in patients with an acute anterior-circulation stroke, thrombolysis plus IV cyclosporine does not significantly decrease 30-day MRI infarct volume compared with thrombolysis alone.
Source: Neurology - June 1, 2015 Category: Neurology Authors: Nighoghossian, N., Berthezene, Y., Mechtouff, L., Derex, L., Cho, T. H., Ritzenthaler, T., Rheims, S., Chauveau, F., Bejot, Y., Jacquin, A., Giroud, M., Ricolfi, F., Philippeau, F., Lamy, C., Turc, G., Bodiguel, E., Domigo, V., Guiraud, V., Mas, J.-L., Op Tags: Clinical trials Randomized controlled (CONSORT agreement), Class I, Infarction ARTICLE Source Type: research